NOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
|
|
- Liliana Ward
- 5 years ago
- Views:
Transcription
1 Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept of net clinical benefit. 2. Describe the role of direct thrombin inhibitors in patients with non-st-segment elevation acute coronary syndrome. 3. Discuss the role of the ACUITY study in determining the optimal anti-thrombin for use in ED patients with non-st-segment elevation acute coronary syndrome. INTRODUCTION Unfractionated heparin (UFH), low molecular weight heparin (LMWH), thienopyridines (clopidogrel), and glycoprotein (GP) IIb/IIIa inhibitors are class I guideline recommendations from the most recent American College of Cardiology/American Heart Association (ACC/AHA) guidelines for the management of patients with non-st-segment elevation acute coronary syndromes (ACS). 1 The use of enoxaparin (a LMWH), rather than UFH, has decreased ischemic complications in patients with ACS who are treated conservatively. 2,3 Reductions in both early and late composite of death and myocardial infarction (MI) are enhanced with early addition of clopidogrel 4-6 and a GP IIb/IIIa inhibitor 7-9 to unfractionated heparin (UFH) and aspirin in patients with ACS. Several trials have established early invasive management as the optimal treatment for patients with moderate-to high-risk ACS and the guidelines have endorsed this approach. 1 An early invasive strategy consists of early initiation of anti-thrombotic and anti-platelet therapy, angiographic assessment within 48 hours, followed by definitive therapy tailored to each patient s coronary anatomy. The ideal anti-thrombotic regimen for patients with ACS should facilitate an early invasive strategy (including percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery, if appropriate); should provide maximal protection from adverse ischemic events; should minimize the risk of hemorrhagic complications; enable more simplified (or emergency department [ED] friendly) treatment pathways; and should be cost-effective. New considerations in trial design: Inclusion of Bleeding Parameters Traditionally, hard outcomes, such as death were considered the ideal outcome parameter for large scale clinical trials. However, improved treatment modalities have resulted in improved outcomes and a reduction in the frequency of death, The ideal anti-thrombotic regimen for patients with ACS should facilitate an early invasive strategy (including percutaneous coronary intervention or coronary artery bypass graft surgery, if appropriate); should provide maximal protection from adverse ischemic events; should minimize the risk of hemorrhagic complications; enable more simplified (or ED friendly) treatment pathways; and should be cost-effective. 23
2 ADVANCING THE STANDARD OF CARE: Cardiovascular and Neurovascular Emergencies such that it is no longer practical as a sole outcome measurement, even in clinical trials with over 10,000 patients. The incremental improvement in mortality is too small to be detected, even with these large trials. Therefore, contemporary studies have used composite efficacy endpoints, comprised of patients that attain any of a combination of outcomes, typically, mortality, myocardial infarction and refractory ischemia (possibly defined by urgent target vessel revascularization). Recently, a new composite has been defined: net clinical benefit, which includes a triple composite efficacy parameter as well as major bleeding complications. The rationale is that short term bleeding complications are associated with worse long term outcomes. 13 Likewise, the need for blood transfusions is associated with increased 30 day mortality even after adjustment for risk factors. 14 It makes sense that the ideal anti-thrombotic therapy should minimize short term bleeding risk to optimize long term outcome. Anti-thrombins Thrombin is the most potent natural platelet activator. 15 Thrombin converts fibrinogen to fibrin, activates coagulation factors V and VIII, accelerates coagulation, stimulates its own generation, and interacts with endothelial cells to upregulate tissue factor Thrombin is pivotal link in the process of tissue injury, coagulation, and the platelet response (Figure 1). Unfractionated heparin, enoxaparin, and fondaparinux are considered indirect thrombin inhibitors because they require binding with circulating anti-thrombin III (an endogenous circulating alpha-globulin) to exert their anticoagulant affect. In contrast to UFH and LMWH, direct thrombin inhibitors interact with circulating and clot-bound thrombin. 20 Bivalirudin, a direct thrombin inhibitor, binds specifically to thrombin at its active catalytic site and at the exosite- 1 docking locus. 21 Bivalirudin competitively inhibits thrombin with high affinity but is a short-acting agent, with a half-life of only 25 minutes (compared with 60 to 90 minutes with UFH). 20,22 It does not require laboratory monitoring due to predictable linear pharmacokinetics. New Clinical Data Since the publication of the 2002 AHA/ACC guidelines for the management of patients with NSTEMI, there have been 3 large pivotal trials regarding anti-thrombin therapy: SYNERGY, OASIS-5, and ACUITY SYNERGY demonstrated that enoxaparin was non-inferior to UFH, with death and MI occurring in 14.0% (n = 696) and 14.5% (n = 722), respectively (hazard ratio 0.96; 95% CI = ). There was a slight excess in bleeding in the enoxaparin group. 23 In OASIS-5 (The Organization Figure 1. The pivotal role of thrombin in the process of tissue injury, coagulation, and the platelet response. AT=anti-thrombin III GPI=glycoprotein IIb/IIIa inhibitors Tissue factor Collagen Aspirin Plasma clotting cascade ADP Fondaparinux Thromboxane A 2 AT Prothrombin LMWH AT Factor Heparin Xa Platelet activation AT Bivalirudin Thrombin Platelet aggregation Ticlopidine Clopidogrel Prasugrel (TIMI-38) Cangrelor (IV) Eptifibatide Abciximab Tirofiban (GPI) Fibrinogen Thrombolytics Fibrin Thrombus 24
3 to Assess Strategies in Acute Ischemic Syndromes) fondaparinux (2.5mg SQ qd) was compared to enoxaparin (1 mg/kg SQ BID) in 20,078 unstable angina or NSTEMI patients with respect to a primary endpoint representing net clinical benefit. 24 This net clinical endpoint was a composite of death, myocardial infarction, and refractory ischemia combined with major bleeding. OASIS-5 found no difference in the efficacy endpoint (fondaparinux, 5.8% versus enoxaparin, 5.9%), however the net clinical benefit outcome favored fondaparinux (hazard ratio, 0.81 (95% CI ). This benefit was due to reduced major bleeding. The Path to ACUITY: bivalirudin Bivalirudin has been extensively investigated in patients undergoing PCI. In the Bivalirudin Angioplasty Trial, 26, patients receiving PCI were randomized to bivalirudin or UFH without GP IIb/IIIa inhibitor use. The bivalirudin-treated patients showed lower rates of ischemic events and hemorrhage A 30% to 60% reduction in ischemic complications (P <.01) and 60% to 80% reduction in bleeding (P <.001) were noted in the 1006 unstable angina patients and the 741 patients following acute myocardial infarction. This trial predated the use of stents, GP IIb/IIIa inhibitors, and thienopyridines, and relatively high UFH doses were used in the control arm. A more contemporary study was performed in the Randomized Evaluation of PCI Linking Bivalirudin to Reduce Clinical Events (REPLACE)-2 trial. 30 REPLACE-2 randomized 6010 patients undergoing stent implantation to UFH and planned GP IIb/IIIa inhibition versus bivalirudin and provisional GP IIb/IIIa inhibition (which was used in only 7.2% of patients). The 30-day composite net clinical benefit (death, MI, urgent repeat revascularization, and major bleeding) was similar between the two groups (10.0% with UFH + routine GP IIb/IIIa inhibition vs 9.2% with bivalirudin and provisional GP IIb/IIIa inhibition, P =.32), as was the rate of death, MI, and urgent revascularization (7.1% vs 7.6%, respectively, P =.40). Major bleeding was less common in the bivalirudin patients (4.1% vs 2.4%, P <.001). 30 These studies demonstrated the utility of bivalirudin in the cardiac catheterization laboratory during angioplasty. It should be noted that the results were similar in the most ED relevant group: the 1340 REPLACE- 2 patients who presented with ACS. The Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial was a large-scale, prospective, multicenter, randomized study designed to determine the optimal anticoagulation regimen in patients with moderate to highrisk ACS undergoing an early invasive strategy. 25 In ACUITY, heparin (either UFH or enoxaparin) and bivalirudin, with or without an upstream GP IIb/IIIa inhibition, was compared to bivalirudin alone in high-risk NSTEMI ACS patients Since the publication of the 2002 AHA/ ACC guidelines for the management of patients with NSTEMI, there have been 3 large pivotal trials regarding anti-thrombin therapy: SYNERGY, OASIS-5, and ACUITY. 25
4 ADVANCING THE STANDARD OF CARE: Cardiovascular and Neurovascular Emergencies treated with a planned early interventional strategy (Figure 2). 25 An important secondary objective was to examine clinical outcomes after GP IIb/IIIa inhibition given upstream (before angiography) versus selective use of GP IIb/IIIa inhibition in patients undergoing PCI only. The results of ACUITY, which were released at the American College of Cardiology Late Breaking Clinical Trials session in March of 2006, demonstrate the beneficial effects of bivalirudin on net clinical benefit (composite of death, AMI, urgent revascularization and major bleeding), predominantly due to reduction in major bleeding. The net clinical benefit endpoint favored bivalirudin monotherapy (10.1%) over heparin with or without upstream GP IIb/ IIIa inhibition (11.7%), and bivalirudin with or without upstream GP IIb/IIIa inhibition (11.8%). The precise role of bivalirudin in the ED will be defined, as ACUITY is further analyzed to determine if ED administration is associated with improved outcomes. Moderatehigh risk ACS Aspirin in all Clopidogrel dosing and timing per local practice R* UFH or Enoxaparin + GP IIb/IIIa Bivalirudin + GP IIb/IIIa Bivalirudin alone Angiography within 72 hours Medical management PCI CABG Figure 2. ACUITY study design in high-risk NSTEMI ACS patients treated with a planned early interventional strategy. The View From the Emergency Department Most emergency physicians are primarily concerned with minimizing the risk of early adverse ischemic outcomes and are inherently less likely to be concerned about procedural complications. On the other hand, interventional cardiologists are also concerned about procedure complications and post-procedure bleeding. Therefore, it is not surprising that emergency physicians and cardiologists might choose different therapies given the same patient. The SYNERGY trial demonstrated that consistent therapy (not changing between UFH and LMWH in either direction) is associated with an improved outcome. The optimum anti-thrombin should enable a seamless transition from the ED to the cardiac catheterization laboratory. It should minimize pre-procedural ischemia and both peri- and post-procedural ischemic and bleeding outcomes, be easy to administer, require no monitoring, and be cost effective. The preliminary data from ACUITY suggest that bivalirudin has improved net clinical benefit. However, several questions remain unanswered: (1) Does starting bivalirudin in the ED, when a patient may or may not receive cardiac catheterization, improve outcomes? (2) In patients who will receive an intervention, is there additional benefit to beginning upstream bivalirudin in the ED or should administration wait until catheterization? Further analysis of the ACUITY trial might help answer these and other questions, was well as determine whether patients benefit from having this therapy initiated in the ED. 26
5 REFERENCES 1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non- ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) Available at: guidelines/unstable/incorporated/index.htm. 2. Cohen M, Demers C, Gurfinkel EP, et al., A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337: Antman EM, McCabe CH, Gurfinkel EP, et al., Enoxaparin prevents death and cardiac ischemic events in unstable angina/non Q-wave myocardial infarction. Circulation 1999;100: Yusuf S, Zhao F, Mehta SR, et al., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: Mehta SR, Yusuf S, Peters RJ, et al., Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention. Lancet 2001;358: Steinhubl SR, Berger PB, Mann JT, et al., Early and sustained dual oral anti-platelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288: PRISM-PLUS Study Investigators, Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q-wave myocardial infarction. N Engl J Med 1998;338: PURSUIT Trial Investigators, Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339: Boersma E, Harrington RA, Moliterno DJ, et al., Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359: Cannon CP, Weintraub WS, Demopoulos LA, et al., Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344: FRISC II Investigators, Invasive compared with non-invasive treatment in unstable coronary-artery disease. Lancet 1999;354: Fox KA, Poole-Wilson PA, Henderson RA, et al., Interventional versus conservative treatment for patients with unstable angina or non-stelevation myocardial infarction. Lancet 2002;360: Rao SV, O Grady K, Pieper K, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005;96: Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292: Ashby CR, Daniel JL, Kunapuli SP and Smith JB, Platelet stimulatory and inhibitory receptors. In: R.W. Colman, Editor, Hemostasis and Thrombosis (4th edition.), Lippincott Williams & Wilkins, Philadelphia, Pa (2001), pp Mann KG, Biochemistry and physiology of blood coagulation. Thromb Haemost 1999;82: Brummel KE, Paradis SG, Butenas S, Mann KG, Thrombin functions during tissue factor induced blood coagulation release and factor XIII activation. Blood 2002:100: Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22: Colman R, Clowes A, James G. Overview of hemostasis. In: R.W. Colman, Editor, Hemostasis and Thrombosis (4th edition.), Lippincott Williams & Wilkins, Philadelphia, PA (2001), pp Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol 2003;41suppl:70S 78S. 21. Weitz JI, Bates ER. Direct thrombin inhibitors in cardiac disease. Cardiovasc Toxicol 2003;3: Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 1996;7: Ferguson JJ, Califf RM, Antman EM, et al., Enoxaparin vs unfractionated heparin in high-risk patients with non-st-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;229: The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5). Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med., 2006;354(14), Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: Study design and rationale. American Heart Journal 2004;148: Bittl JA, Chaitman BR, Feit F, et al., Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina. Am Heart J 2001;142: Henry TD. Overcoming heparin limitations in high-risk percutaneous coronary intervention: the alternative strategy: replacing heparin with bivalirudin. J Invasive Cardiol 2002;(14 suppl B):19B 29B. 28. Bittl JA, Strony J, Brinker JA, et al., Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333: Bittl JA, Feit F. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Am J Cardiol 1998;82: 43P 49P. 30. Lincoff AM, Bittl JA, Harrington RA, et al., Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 2003;289: Copyright EMCREG-International,
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More information2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY
2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA Professor and Chairman, Department of Emergency
More informationAnticoagulation therapy in acute coronary syndromes according to current guidelines
Acute management of ACS Anticoagulation therapy in acute coronary syndromes according to current guidelines Marcin Grabowski, Marcin Leszczyk, Andrzej Cacko, Krzysztof J. Filipiak, Grzegorz Opolski 1 st
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin, 250mg powder for concentrate for solution for injection or infusion (Angiox ) No. (516/08) The Medicines Company UK Ltd 07 November 2008 The Scottish Medicines
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationIs the role of bivalirudin established?
Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationNEW CONCEPTS AND EMERGING TECHNOLOGIES FOR EMERGENCY PHYSICIANS
SEPTEMBER 2007 volume 5 C O L L A B O R AT E I N V E S T I G AT E E D U C AT E Use of Direct Thrombin Inhibitors for Treating Non-ST-Segment Elevation Acute Coronary Syndromes in Special Patient Groups:
More informationAcute Coronary Syndromes: Selective vs Early Invasive Strategies
Acute Coronary Syndromes: Selective vs Early Invasive Strategies WilliamE.Boden,MD,FACCandVipulGupta,MBBS,MPH Division of Cardiovascular Medicine, University at Buffalo Schools of Medicine and Public Health,
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationJournal of the American College of Cardiology Vol. 51, No. 18, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 51, No. 18, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.12.052
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationReport on New Patented Drug - Angiomax
Report on New Patented Drug - Angiomax March 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationMortality from ST-segment elevated acute
Choosing Pharmacotherapy for Primary PCI in Acute Myocardial Infarction A review of the agents and strategies commonly used during percutaneous intervention for ST-segment elevated myocardial infarction.
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationIs there a real need for new agents to optimize efficacy/safety balance
Anticoagulation in acute coronary syndrome Is there a real need for new agents to optimize efficacy/safety balance Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationPathophysiology of ACS
Pathophysiology of ACS ~ 2.0 MM patients admitted to CCU or telemetry annually 0.6 MM ST-segment elevation MI 1.4 MM Non-ST-segment elevation ACS NSTEMI vs STEMI VANQWISH Boden et al N Engl J Med 1998;338:1785-1792
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin 250mg for injection or infusion (Angiox ) (156/05) Nycomed UK Ltd No. 4 February, 2005 The Scottish Medicines Consortium has completed its assessment of the above
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationSTEMI: Newer Aspects in Pharmacological Treatment
CHAPTER 14 STEMI: Newer Aspects in Pharmacological Treatment P. C. Manoria, Pankaj Manoria Introduction ST elevation myocardial infarction (STEMI) commonly results from disruption of a vulnerable plaque
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationObjectives. Introduction
MARCH 2007 VOLUME 2 COLLABORATE INVESTIGATE EDUCATE Direct Thrombin Inhibitors in Non-ST-segment Elevation Acute Coronary Syndromes Dear Colleagues, For patients with non-st-segment elevation acute coronary
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationAnti-thrombotic management in interventional cardiology
Chapter 8 Anti-thrombotic management in interventional cardiology James Tcheng, Steve Kindsvater Introduction Since the dawn of the interventional age, the need for anti-thrombotic therapy during percutaneous
More informationPercutaneous coronary intervention (PCI), in
ECONOMIC IMPLICATIONS OF THE USE OF DIRECT THROMBIN INHIBITORS IN PERCUTANEOUS CORONARY INTERVENTION David J. Cohen, MD, MSc * ABSTRACT More than 1.2 million percutaneous coronary intervention (PCI) procedures
More informationIschemic events and bleeding complications after primary percutaneous coronary intervention Kikkert, Wouter
UvA-DARE (Digital Academic Repository) Ischemic events and bleeding complications after primary percutaneous coronary intervention Kikkert, Wouter Link to publication Citation for published version (APA):
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationDefining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention
Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention Aggregate Results From 6 Randomized, Controlled Trials Derek P. Chew, MBBS; Deepak L. Bhatt, MD; A. Michael Lincoff,
More informationAntithrombotic Strategy in Non ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 6, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.03.015 Antithrombotic
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationAntiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital
Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital Authors G. Mason*, F. Wirth**, A. Cignarella***, R.G. Xuereb****, L.M. Azzopardi***** *Final Year
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationJournal of the American College of Cardiology Vol. 52, No. 22, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 22, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.021
More informationAcute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC
Acute Coronary Syndromes January 9, 2013 Chris Chiles M.D. FACC Disclosures None- not even a breakfast burrito from a drug company Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes* 1.57
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationAn Update on Oral Anti-platelet therapy in patients with non-st Myocardial Infarction. Disclosures
An Update on Oral Anti-platelet therapy in patients with non-st Myocardial Infarction R. Scott Wright, MD, FACC, FESC, FAHA, Professor of Medicine Mayo Clinic Fall Managed Care Forum November 2013 3098590-1
More informationManagement of Acute Coronary Syndromes
Management of Acute Coronary Syndromes Objectives 1. To outline the approach in managing a patient who presents with an acute coronary syndrome focusing on anti- thrombotic agents. Jenny Chiu, BScPhm,
More informationACUTE CORONARY SYNDROME
A supplement to MONTHLY PRESCRIBING REFERENCE April 2014 Issue #18 Intervention & Prevention: Keeping Current with ACUTE CORONARY SYNDROME JOURNAL CLUB Pretreatment with prasugrel in non-st-segment elevation
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationGuidelines and Performance Measures for the Management of Acute Coronary Syndrome
Guidelines and Performance Measures for the Management of Acute Coronary Syndrome Piotr Sobieszczyk, MD ABSTRACT BACKGROUND: Acute coronary syndrome (ACS) is caused by reduced perfusion of the myocardium
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More information2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02963-7
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationThe Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non ST-Elevation Acute Coronary Syndrome The Clopidogrel in Unstable angina to prevent
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More informationThe Thrombolysis In Myocardial Infarction Risk Score in Unstable Angina/ Non ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)03019-x
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationCHAPTER 17 Antithrombotic Agents Heparins
CHAPTER 17 Antithrombotic Agents Heparins Structure Mechanism of Action Pharmacokinetics Limitations of Unfractionated Heparin Heparin Induced Thrombocytopenia Heparin Rebound Low Molecular Weight Heparins
More informationPre-Procedural Estimate of Individualized Bleeding Risk Impacts Physicians Utilization of Bivalirudin During Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 61, No. 18, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.017
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationAnticoagulation Update David J. Moliterno, MD
David J., MD Anticoagulant Agents n Cardiovascular Medicine: An Update David J., MD Professor and Chairman Division of Cardiovascular Medicine The University of Kentucky Linda and Jack Gill Heart nstitute
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationProspective Comparison of Hemorrhagic Complications After Treatment With Enoxaparin
Prospective Comparison of Hemorrhagic Complications After Treatment With Versus Unfractionated Heparin for Unstable Angina Pectoris or Non ST-Segment Elevation Acute Myocardial Infarction Scott D. Berkowitz,
More informationDisclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None
Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationDoes VALIDATE-SWEDEHEART invalidate the use of bivalirudin in myocardial infarction?
Editorial Does VALIDATE-SWEDEHEART invalidate the use of bivalirudin in myocardial infarction? Caroline Ong, Sripal Bangalore New York University School of Medicine, New York, NY, USA Correspondence to:
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationThe restoration of coronary flow after an
Pharmacological Reperfusion in Acute Myicardial Infarction after ASSENT 3 and GUSTO V [81] DANIEL FERREIRA, MD, FESC Serviço de Cardiologia, Hospital Fernando Fonseca, Amadora, Portugal Rev Port Cardiol
More informationOriginal Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice
Am J Cardiovasc Dis 2012;2(3):248-252 www.ajcd.us /ISSN:2160-200X/AJCD1204002 Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice Angela
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationThe use of percutaneous coronary intervention (PCI) as
Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Jeffrey J. Popma, MD; Peter Berger, MD; E. Magnus Ohman, MD, FCCP;
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationDirect Thrombin Inhibitors and Gp 2b/3a Receptor Blockers in the Cardiac Cath Lab. Eric J Dippel, MD FACC
Midwest Cardiovascular Research Foundation Direct Thrombin Inhibitors and Gp 2b/3a Receptor Blockers in the Cardiac Cath Lab Eric J Dippel, MD FACC Plaque Rupture Stable Angina Unstable Angina Non Q-wave
More informationChapter 15 Glycoprotein IIb/IIIa Antagonists
Chapter 15 Glycoprotein IIb/IIIa Antagonists Introduction - GP IIb/IIIa receptors - Pharmacologic approaches - Preparations and dosages Mechanism of Action Clinical Efficacy - UA / NSTEMI - STEMI - PCI
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationAntiplatelet therapy is the mainstay of pharmacological
Contemporary Reviews in Interventional Cardiology Pretreatment With Antiplatelet Drugs in Invasively Managed Patients With Coronary Artery Disease in the Contemporary Era Review of the Evidence and Practice
More information